hrp0084p2-354 | Fat | ESPE2015

Overweight and Obesity in Childhood Cancer Survivors

Denzer Christian , Breuninger Louise , Steinbach Daniel , Cario Holger , Debatin Klaus-Michael , Wabitsch Martin

Background: Obesity is a potential late-effect of therapies for childhood cancer. Reported prevalence rates of obesity in childhood cancer survivors are heterogenous and currently unavailable for children treated according to protocols of the German Society for Paediatric Oncology. Furthermore, risk factors for the development of obesity following childhood cancer remain largely unknown.Methods: From a cohort of n=149 patients followed in a late...

hrp0084p2-497 | Perinatal | ESPE2015

Genetic Variation in the FSH Signalling Pathway Affects Female Reproductive Hormones During Infancy

Henriksen Louise S , Hagen Casper P , Assens Maria , Almstrup Kristian , Main Katharina M

Background: Studies have shown that genetic variations in the FSH pathway (SNPs: FSHB −211G>T, FSHR −29G>A, and FSHR 2039A>G) affect peripubertal levels of serum FSH and age at pubertal onset in girls.Objective and hypotheses: Genetic variations in the FSH pathway reflect circulating levels of female reproductive hormones during the postnatal gonadotropin surge.Method: Blood samples were taken in girls of th...

hrp0084p3-711 | Diabetes | ESPE2015

Heterogeneous Presentation of Paediatric Hyperglycaemic Hyperosmolar State – A Case Series

Mohamed Zainaba , Randell Tabitha , Sundaram Prem , Greening James , Denvir Louise , Sachdev Pooja

Background: The hyperosmolar hyperglycaemic state (HHS) is rare, but recognised, life-threatening clinical entity in children with type 2 diabetes (T2DM). It is also reported as presenting feature in other types of diabetes and metabolic disorders. The estimated mortality in HHS is 10–20%, ten times higher than Diabetic Ketoacidosis (DKA).The mainstay of management involves aggressive fluid therapy with insulin and managing complications namely; rhabdomyolysis, multi-orga...

hrp0094p1-40 | Fat, Metabolism and Obesity A | ESPE2021

Liraglutide for the Management of Childhood Obesity

Apperley Louise , Erlandson-Parry Karen , Gait Lucy , Laing Peter , Senniappan Senthil ,

Introduction: The prevalence of childhood obesity is continuing to increase worldwide and has become a major health concern. There are a number of serious complications to childhood obesity with significant long-term health implications if not managed in a timely matter. These complications include type 2 diabetes mellitus (T2DM), obstructive sleep apnoea (OSA), idiopathic intracranial hypertension (IIH) and non-alcoholic fatty liver disease (NAFLD). At presen...

hrp0094p1-65 | Diabetes B | ESPE2021

Efficacy of Use of Continuous Glucose Monitoring System in patients with Congenital Hyperinsulinism

Tropeano Yesica , Purushothaman Preetha , Gilbert Clare , Morgan Kate , Doodson Louise , Dastamani Antonia ,

Background: Hypoglycaemic episodes in patients with Congenital Hyperinsulinism (CHI) are not always detected due to the intermittent measurement of blood glucose concentrations, particularly the asymptomatic episodes. Detecting and treating these episodes is important for prevention of hypoglycaemic brain injury. Although the Continuous Glucose Monitoring System (CGMS) is widely used in adults and children with diabetes, the use in patients with CHI remains li...

hrp0094p1-121 | Growth A | ESPE2021

Higher rates of non-skeletal complications in achondroplasia compared to the general population: a UK matched cohort study using the CPRD database

Pimenta Jeanne M. , Cheung Moira , Irving Melita , Mazzeo Louise , Landis Sarah , Mukherjee Swati ,

Objectives: Achondroplasia (ACH) is a rare, genetic skeletal dysplasia, resulting in impaired endochondral bone growth and leading to multisystem complications. We aimed to estimate rates of non-skeletal complications in ACH patients compared with general population controls.Methods: Retrospective cohort study using UK Clinical-Practice-Research-Datalink (CPRD-GOLD), identifying an ACH cohort. Study index date was define...

hrp0094p2-198 | Fat, metabolism and obesity | ESPE2021

Successful weight loss and resolution of hepatic fibrosis in a girl with severe obesity

Apperley Louise , Erlandson-Parry Karen , Clarke Ellie , Gait Lucy , Auth Marcus , Senniappan Senthil ,

Introduction: Childhood obesity is continuing to increase worldwide resulting in a rise in the number of individuals with complications secondary to obesity. Non-alcoholic fatty liver disease (NAFLD) is seen in both adult and paediatric populations and if not treated appropriately is potentially life-threatening, as it may progress to advanced fibrosis, cirrhosis or hepatocellular carcinoma. NAFLD has now become the most common indication for liver transplant ...

hrp0098fc1.5 | Diabetes and Insulin | ESPE2024

The Side-Effects of Lanreotide in Children with Congenital Hyperinsulinism (CHI): A Decade-long Exploration

Malhotra Neha , Yan Georgina , Morgan Kate , Gilbert Clare , Doodson Louise , Gan Chin , Dastamani Antonia

Background: Lanreotide, a prolonged-release somatostatin analogue, has been utilized off-label for nearly a decade to treat cases of congenital hyperinsulinism (CHI) that do not respond to diazoxide. Acute side-effects of Lanreotide include diarrhoea and topical allergic reactions. Long-term effects include hepatitis, gallstones, growth suppression, hypothyroidism and gastrointestinal dysmotility. However, limited number of case series have documented the long...

hrp0098fc10.1 | Multisystem Endocrine Disorders | ESPE2024

Genetic screening and tumour surveillance program outcomes in rare paediatric hereditary endocrine tumour syndromes

Oprea Alina , Izatt Louise , Ajzensztejn Michal , Snow Emma , Carroll Paul , Wei Christina

Background: Hereditary syndromic endocrine tumours are associated with significant morbidity in the paediatric population. Advances in molecular genetics enable early cascade genetic testing with early initiation of tumour screening. Controversy exists around the start age and burdens arising from screening-related harms.Objective: To describe the efficiency of the screening program for paediatric patients with genetic r...

hrp0098fc10.2 | Multisystem Endocrine Disorders | ESPE2024

Characterising the natural history of Multiple Endocrine Neoplasia 2B caused by M918T RET pathogenic variants in children and young people

McGlacken-Byrne Sinead , Butler Colin , Abdel Aziz Tarek , Izatt Louise , Brain Caroline , Kurzawinski Tom

Aim: We describe the natural history, treatment, and clinical outcomes of Multiple Endocrine Neoplasia type 2B (MEN2B) caused by the M918T RET pathogenic variant.Methods: Retrospective case notes review of all young people <18 years presenting to a quaternary paediatric endocrinology referral centre in the UK between 2005-2023 who have MEN2B caused by the M918T pathogenic variant in the RET proto-onc...